Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D. Read more about Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D.
Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors Read more about Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors
Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development Read more about Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development
Xencor Reports First Quarter 2019 Financial Results Read more about Xencor Reports First Quarter 2019 Financial Results
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors Read more about Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors
Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019 Read more about Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019
Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045 Read more about Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045
Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program Read more about Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program
Xencor to Participate in Upcoming Investor Conferences Read more about Xencor to Participate in Upcoming Investor Conferences
